Cassava Sciences is working on bringing its own Alzheimer ... there hangs a dark cloud of a previous US Securities & Exchange Commission (SEC) charge against former members of Cassava’s ...

BioSpace takes a look at the headlines across a heavy earnings week for biotechs, checking in on Allogene, Rapport and more.

SEC adopts EDGAR Next - As outlined in this October 22 Cooley alert, the Securities and Exchange Commission (SEC) adopted final ...

Cassava Sciences Inc. is a clinical-stage biotechnology company dedicated ... The company recently resolved an SEC ...

Ms. Nassif brings an extensive track record of successfully developing commercial strategies for multiple FDA-approved drugsAppointment initiates ...

Bearish flow noted in Cassava Sciences (SAVA) with 3,180 puts trading, or 1.8x expected. Most active are 11/22 weekly 13 puts and 11/22 weekly 25 puts, with total volume in those strikes near 1,000 ...

Cassava Sciences (NASDAQ:SAVA) has tapped Freda Nassif as chief commercial officer, effective Nov. 18, 2024. Ms. Nassif is an ...

On Friday, Cassava Sciences Inc (SAVA) stock saw a modest uptick, ending the day at $26.91 which represents a slight increase of $0.77 or 2.95% from the prior close of $26.14. The stock opened at $26.

STAT+ subscribers can sign up here to get it delivered to their inbox. As we count down toward the December readout of ...

The Medical group has plenty of great stocks, but investors should always be looking for companies that are outperforming their peers. Cassava Sciences, Inc. (SAVA) is a stock that can certainly grab ...

ByInvesting.com • Aug 07, 2024 SAVA stock soars to 52-week high, reaching $32.29 Cassava Sciences Inc. (NASDAQ:SAVA) stock has achieved a notable milestone, soaring to a 52-week high of $32.29.

AUSTIN, Texas - Cassava Sciences, Inc. (NASDAQ:SAVA), a clinical-stage biotech company, announced today that an independent Data and Safety Monitoring Board (DSMB) has completed a... ByInvesting ...